A Phase 3 interventional study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 30 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 17th largest by enrollment, is one of 7 that started in 2010, is one of 14 in phase 3, and was the 18th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 86th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 110th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination inhaled corticosteroid and long-acting beta2-agonist
Drug: Fluticasone Furoate/GW642444 Inhalation Powder
Inhaled corticosteroid
Drug: Fluticasone Furoate Inhalation Powder
Drug pages: Fluticasone furoate · Vilanterol
Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAE.
Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Laboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (BL) (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Laboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Number of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD
Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace (TRA), 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Change From Baseline in the 24-hour Urinary Cortisol Excretion
Urine samples were collected for measurement of urinary cortisol excretion at the following scheduled time points: Baseline (Week 0), Week 24, and Week 52/WD. The 24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
Time frame: Baseline (Week 0), Week 24, and Week 52/WD
Change From Baseline in Blood Pressure
Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Week 0), Week 12, Week 24, and Week 52/WD
Change From Baseline in Heart Rate (HR)
Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Week 0), Week 12, Week 24, and Week 52/WD
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Baseline\[Week -2\], Week 12, 24 and Week 52/WD) in the treatment period. Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal (Abn) findings. Any abnormal ECG, including those that worsen from Baseline, and determined clinically significant by the assessment of the investigator were recorded as CS.
Time frame: Week 12, Week 24, and Week 52/WD
Number of Participants With Severe Asthma Exacerbation During the Study Treatment
A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.
Time frame: Baseline up to Week 52
Change From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment
Change from Baseline in AM and PM PEF at 52 weeks of evaluation period during study treatment was recorded in the dairy record card. The Baseline value was calculated as the mean of all available data recorded during the7 days immediately prior to the treatment start date (including Day 1: Day 1 is treatment start date). The PEF is defined as the greatest rate of airflow that can be achieved during forced exhalation beginning with the lungs fully inflated.
Time frame: Baseline up to Week 52
Change From Baseline in Asthma Symptom Score During the Study Treatment
The Baseline value was calculated as the mean of all available data recorded during the 7 days immediately prior to Visit 2 (treatment assignment visit). Participants entered their asthma symptom score in the patient diary twice daily (morning and evening). Daytime asthma symptom scores: 0-no asthma symptoms, 1-one episode of short-time asthma symptoms, 2-two or more episodes of short-time asthma symptoms, 3-asthma symptoms occurring during most part of daytime without interference with daily life activities, 4-asthma symptoms occurring during most part of daytime with interference with daily life activities, 5-severe asthma symptoms that disable working or daily life activities. Nighttime asthma symptom scores: 0-no asthma symptoms, 1-one awakening due to asthma symptoms, 2-two or more awakenings due to asthma symptoms, 3-asthma symptoms almost prevented the participant from sleeping, 4-severe asthma symptoms completely prevented from sleeping.
Time frame: Baseline up to Week 52
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment
Participants who were symptom free for 24-hours were assessed. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.
Time frame: Baseline up to Week 52
Change From Baseline in the Percentage of Rescue-free 24-hour Periods
The time span during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.
Time frame: Baseline up to Week 52
Number of Rescue Medication Inhalations
Salbutamol inhaler was used as the rescue medication. Participants entered the number of rescue medication inhalations in the patient diary twice daily (morning and evening).
Time frame: Baseline up to Week 52
| Milestone | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Started | 60 | 93 | 90 |
| Completed | 55 | 79 | 86 |
| Not completed | 5 | 14 | 4 |
| Withdrew: Adverse event | 2 | 11 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Protocol defined stopping criteria | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 2 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAE.
| Participants | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Any SAE | 4 | 7 | 1 |
| Any Non-serious AE | 52 | 77 | 72 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| Percentage | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Basophils, Baseline, n=60,93,90 | 0.78 ± 0.509 | 0.71 ± 0.419 | 0.79 ± 0.508 |
| Basophils, Week 12, n=58, 90, 87 | 0.76 ± 0.473 | 0.67 ± 0.414 | 0.79 ± 0.542 |
| Basophils, Week 24, n=58, 83, 86 | 0.74 ± 0.510 | 0.66 ± 0.392 | 0.72 ± 0.408 |
| Basophils, Week 52/WD, n=60, 90, 89 | 0.77 ± 0.510 | 0.64 ± 0.383 | 0.72 ± 0.482 |
| Eosinophils, Baseline, n=60,93,90 | 5.59 ± 4.476 | 5.03 ± 3.843 | 5.32 ± 3.167 |
| Eosinophils, Week 12, n=58, 90, 87 | 5.22 ± 3.257 | 4.01 ± 3.112 | 4.90 ± 3.496 |
| Eosinophils, Week 24, n=58, 83, 86 | 4.88 ± 3.678 | 4.00 ± 2.753 | 4.37 ± 3.061 |
| Eosinophils, Week 52/WD, n=60, 90, 89 | 4.89 ± 3.981 | 4.27 ± 3.247 | 4.60 ± 3.090 |
| Lymphocytes, Baseline, n=60, 93, 90 | 30.49 ± 5.948 | 30.95 ± 7.504 | 31.26 ± 6.150 |
| Lymphocytes, Week 12, n=58, 90, 87 | 29.22 ± 6.891 | 29.15 ± 6.378 | 29.35 ± 7.274 |
| Lymphocytes , Week 24, n=58, 83, 86 | 29.06 ± 6.269 | 28.40 ± 6.282 | 28.83 ± 6.343 |
| Lymphocytes, Week 52/WD, n=60, 90, 89 | 30.01 ± 6.702 | 27.67 ± 7.913 | 29.04 ± 7.047 |
| Monocytes, Baseline, n=60,93,90 | 5.23 ± 1.307 | 5.39 ± 1.408 | 5.35 ± 1.442 |
| Monocytes, Week 12, n=58, 90, 87 | 5.65 ± 1.187 | 5.61 ± 1.626 | 5.65 ± 1.639 |
| Monocytes, Week 24, n=58, 83, 86 | 5.51 ± 1.571 | 5.52 ± 1.321 | 5.41 ± 1.370 |
| Monocytes, Week 52/WD, n=60, 90, 89 | 5.59 ± 1.637 | 5.72 ± 1.366 | 5.59 ± 1.516 |
| Total neutrophils, Baseline, n=60,93,90 | 57.91 ± 8.064 | 57.92 ± 8.103 | 57.28 ± 7.467 |
| Total neutrophils, Week 12, n=58, 90, 87 | 59.14 ± 7.785 | 60.57 ± 7.474 | 59.31 ± 8.642 |
| Total neutrophils, Week 24, n=58, 83, 86 | 59.82 ± 7.893 | 61.37 ± 6.790 | 60.64 ± 7.358 |
| Total neutrophils, Week 52/WD, n=60, 90, 89 | 58.54 ± 8.910 | 61.70 ± 8.326 | 60.05 ± 7.883 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| 10^9 per liter (Gi/L) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Eosinophils, Baseline, n=60, 93, 90 | 0.338 ± 0.2514 | 0.323 ± 0.2591 | 0.323 ± 0.2042 |
| Eosinophils, Week 12, n=58, 90, 87 | 0.306 ± 0.2106 | 0.245 ± 0.2057 | 0.286 ± 0.2154 |
| Eosinophils, Week 24, n=58, 83, 86 | 0.282 ± 0.2244 | 0.247 ± 0.1864 | 0.256 ± 0.1907 |
| Eosinophils, Week 52/WD, n=60, 90, 89 | 0.290 ± 0.2399 | 0.281 ± 0.2332 | 0.285 ± 0.2032 |
| Platelet count, Baseline, n=60, 93, 90 | 252.4 ± 53.41 | 257.1 ± 64.98 | 254.1 ± 60.77 |
| Platelet count, Week 12, n=58, 90, 87 | 263.9 ± 62.25 | 269.3 ± 60.55 | 259.0 ± 54.00 |
| Platelet count, Week 24, n=58, 83, 86 | 261.1 ± 62.25 | 270.2 ± 66.60 | 260.1 ± 58.84 |
| Platelet count, Week 52/WD, n=60, 90, 89 | 267.2 ± 54.93 | 276.7 ± 68.64 | 270.3 ± 63.75 |
| WBC, Baseline, n=60, 93, 90 | 6.24 ± 1.716 | 6.39 ± 1.503 | 6.13 ± 1.495 |
| WBC, Week 12, n=58, 90, 87 | 5.90 ± 1.642 | 6.11 ± 1.462 | 5.95 ± 1.636 |
| WBC, Week 24, n=58, 83, 86 | 5.86 ± 1.541 | 6.19 ± 1.743 | 6.01 ± 1.564 |
| WBC, Week 52/WD, n=60, 90, 89 | 6.11 ± 1.625 | 6.45 ± 1.530 | 6.24 ± 1.511 |
| Total neutrophils, Baseline, n=60, 93, 90 | 3.661 ± 1.3444 | 3.734 ± 1.2446 | 3.536 ± 1.1080 |
| Total neutrophils, Week 12, n=58, 90, 87 | 3.522 ± 1.2140 | 3.729 ± 1.1131 | 3.567 ± 1.2419 |
| Total neutrophils, Week 24, n=58, 83, 86 | 3.522 ± 1.1186 | 3.833 ± 1.2812 | 3.690 ± 1.2837 |
| Total neutrophils, Week 52/WD, n=60, 90, 89 | 3.585 ± 1.2570 | 4.010 ± 1.2422 | 3.795 ± 1.2221 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| Grams per liter (g/L) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Baseline, n=60, 93, 90 | 135.7 ± 15.88 | 141.1 ± 16.34 | 138.6 ± 15.61 |
| Week 12, n=58, 90, 87 | 138.2 ± 15.10 | 140.6 ± 15.58 | 139.1 ± 14.47 |
| Week 24, n=58, 83, 86 | 137.4 ± 15.45 | 140.8 ± 15.99 | 139.0 ± 14.92 |
| Week 52/WD, n=60, 90, 89 | 136.4 ± 14.16 | 139.0 ± 15.91 | 136.7 ± 15.62 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| Proportions of I | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Baseline, n=60, 93, 90 | 0.4214 ± 0.04429 | 0.4374 ± 0.04417 | 0.4319 ± 0.04090 |
| Week 12, n=58, 90, 87 | 0.4288 ± 0.04224 | 0.4325 ± 0.04199 | 0.4283 ± 0.03870 |
| Week 24, n=58, 83, 86 | 0.4238 ± 0.04228 | 0.4333 ± 0.04277 | 0.4288 ± 0.03858 |
| Week 52/WD, n=60, 90, 89 | 0.4194 ± 0.03921 | 0.4272 ± 0.04367 | 0.4215 ± 0.04138 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| 10^12 per liter (Ti/L) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Baseline, n=60, 93, 90 | 4.557 ± 0.4987 | 4.714 ± 0.4804 | 4.689 ± 0.4493 |
| Week 12, n=58, 90, 87 | 4.656 ± 0.4540 | 4.685 ± 0.4888 | 4.696 ± 0.4267 |
| Week 24, n=58, 83, 86 | 4.626 ± 0.4679 | 4.687 ± 0.4898 | 4.681 ± 0.4357 |
| Week 52/WD, n=60, 90, 89 | 4.603 ± 0.4469 | 4.671 ± 0.5082 | 4.664 ± 0.4643 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| g/L | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Albumin, Baseline, n=60, 93, 90 | 44.3 ± 2.72 | 44.8 ± 2.59 | 44.7 ± 2.86 |
| Albumin, Week 12, n=58, 90, 87 | 44.3 ± 2.37 | 44.1 ± 2.66 | 44.3 ± 2.69 |
| Albumin, Week 24, n=58, 83, 86 | 43.6 ± 2.52 | 43.9 ± 2.67 | 43.7 ± 2.69 |
| Albumin, Week 52/WD, n=60, 90, 89 | 43.5 ± 2.49 | 43.4 ± 3.03 | 43.8 ± 2.72 |
| TP, Baseline, n=60, 93, 90 | 73.3 ± 4.36 | 73.6 ± 3.62 | 74.6 ± 4.08 |
| TP, Week 12, n=58, 90, 87 | 73.8 ± 3.70 | 73.0 ± 3.83 | 74.4 ± 4.56 |
| TP, Week 24, n=58, 83, 86 | 72.3 ± 4.49 | 72.4 ± 3.92 | 73.3 ± 3.78 |
| TP, Week 52/WD, n=60, 90, 89 | 71.5 ± 3.55 | 71.4 ± 3.60 | 72.5 ± 4.15 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (BL) (Week -2), Week 12, Week 24 and Week 52/WD.
| International unit per liter (IU/L) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| AP, Baseline, n=60, 93, 90 | 209.9 ± 57.34 | 222.7 ± 62.97 | 217.1 ± 64.13 |
| AP, Week 12, n=58, 90, 87 | 217.9 ± 56.39 | 214.9 ± 56.73 | 220.3 ± 59.92 |
| AP, Week 24, n=58, 83, 86 | 212.3 ± 59.48 | 216.4 ± 57.33 | 215.9 ± 58.96 |
| AP, Week 52/WD, n=60, 90, 89 | 223.1 ± 64.76 | 219.9 ± 60.27 | 217.0 ± 57.89 |
| ALT, Baseline, n=60, 93, 90 | 19.0 ± 9.69 | 22.3 ± 14.46 | 21.9 ± 16.43 |
| ALT, Week 12, n=58, 90, 87 | 24.1 ± 23.12 | 21.3 ± 11.39 | 20.7 ± 11.44 |
| ALT, Week 24, n=58, 83, 86 | 19.0 ± 11.52 | 20.7 ± 10.45 | 20.1 ± 10.35 |
| ALT, Week 52/WD, n=60, 90, 89 | 21.8 ± 12.46 | 23.2 ± 13.52 | 23.0 ± 14.11 |
| AST, Baseline, n=60, 93, 90 | 20.0 ± 5.48 | 22.0 ± 7.50 | 21.5 ± 8.99 |
| AST, Week 12, n=58, 90, 87 | 23.2 ± 10.08 | 22.0 ± 7.59 | 21.7 ± 6.90 |
| AST, Week 24, n=58, 83, 86 | 20.1 ± 5.72 | 21.2 ± 7.29 | 20.6 ± 6.02 |
| AST, Week 52/WD, n=60, 90, 89 | 23.5 ± 9.47 | 23.3 ± 7.53 | 22.8 ± 6.75 |
| Creatine Kinase, Baseline, n=60, 93, 90 | 111.9 ± 56.95 | 149.8 ± 134.73 | 104.0 ± 45.88 |
| Creatine Kinase, Week 12, n=58, 90, 87 | 118.9 ± 84.32 | 134.0 ± 114.92 | 97.4 ± 39.32 |
| Creatine Kinase, Week 24, n=58, 83, 86 | 115.4 ± 77.09 | 131.9 ± 118.86 | 103.0 ± 58.40 |
| Creatine Kinase, Week 52/WD, n=60, 90, 89 | 105.3 ± 48.78 | 126.6 ± 105.24 | 99.9 ± 48.96 |
| GGT, Baseline, n=60, 93, 90 | 25.4 ± 14.04 | 34.9 ± 42.70 | 30.0 ± 28.96 |
| GGT, Week 12, n=58, 90, 87 | 28.1 ± 15.29 | 31.0 ± 32.21 | 28.2 ± 24.60 |
| GGT, Week 24, n=58, 83, 86 | 24.7 ± 14.73 | 30.8 ± 39.66 | 26.5 ± 22.28 |
| GGT, Week 52/WD, n=60, 90, 89 | 28.2 ± 16.85 | 34.6 ± 48.03 | 28.9 ± 24.59 |
| LDH, Baseline, n=60, 93, 90 | 176.7 ± 23.78 | 186.9 ± 34.40 | 175.3 ± 27.97 |
| LDH, Week 12, n=58, 90, 87 | 180.8 ± 32.66 | 185.7 ± 37.83 | 175.1 ± 28.03 |
| LDH, Week 24, n=58, 83, 86 | 175.3 ± 29.35 | 184.4 ± 36.45 | 174.3 ± 27.84 |
| LDH, Week 52/WD, n=60, 90, 89 | 179.5 ± 31.50 | 188.1 ± 39.96 | 177.9 ± 29.66 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| Micromoles per Liter (µmol/L) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| direct [BD], Baseline, n=60, 93, 90 | 3.220 ± 1.4459 | 3.236 ± 1.5838 | 3.401 ± 1.7851 |
| direct [BD], Week 12, n=58, 90, 87 | 2.948 ± 1.2729 | 3.230 ± 1.5475 | 3.125 ± 1.6535 |
| direct [BD], Week 24, n=58, 83, 86 | 3.214 ± 1.5717 | 3.338 ± 1.8484 | 2.903 ± 1.5970 |
| direct [BD], Week 52/WD, n=60, 90, 89 | 2.850 ± 1.2057 | 3.344 ± 1.5574 | 3.055 ± 1.5569 |
| indirect [BI], Baseline, n=60, 93, 90 | 7.495 ± 2.9883 | 7.079 ± 3.3788 | 7.125 ± 2.8688 |
| indirect [BI], Week 12, n=58, 90, 87 | 7.017 ± 3.1004 | 7.600 ± 3.2131 | 6.938 ± 3.0451 |
| indirect [BI], Week 24, n=58, 83, 86 | 7.842 ± 5.1553 | 7.747 ± 3.7420 | 6.760 ± 3.2222 |
| indirect [BI], Week 52/WD, n=60, 90, 89 | 6.640 ± 2.7100 | 7.505 ± 3.5676 | 6.936 ± 3.4525 |
| total [BT], Baseline, n=60, 93, 90 | 10.716 ± 4.1989 | 10.315 ± 4.7735 | 10.526 ± 4.3571 |
| total [BT], Week 12, n=58, 90, 87 | 9.965 ± 4.1781 | 10.830 ± 4.5424 | 10.063 ± 4.3902 |
| total [BT], Week 24, n=58, 83, 86 | 11.056 ± 6.4954 | 11.084 ± 5.4427 | 9.663 ± 4.4958 |
| total [BT], Week 52/WD, n=60, 90, 89 | 9.491 ± 3.6503 | 10.849 ± 4.8513 | 9.991 ± 4.7177 |
| Creatinine, Baseline, n=60, 93, 90 | 61.8800 ± 13.37091 | 66.4806 ± 15.94483 | 62.0568 ± 12.65536 |
| Creatinine, Week 12, n=58, 90, 87 | 59.3042 ± 13.92743 | 62.9408 ± 15.71444 | 60.1628 ± 13.02866 |
| Creatinine, Week 24, n=58, 83, 86 | 59.7614 ± 12.91371 | 64.5213 ± 15.90631 | 60.6773 ± 13.02242 |
| Creatinine, Week 52/WD, n=60, 90, 89 | 60.4067 ± 12.52458 | 64.6204 ± 16.01762 | 61.3536 ± 14.38660 |
| Uric acid, Baseline, n=60, 93, 90 | 304.0419 ± 90.67062 | 305.7784 ± 78.88104 | 310.6178 ± 96.11471 |
| Uric acid, Week 12, n=58, 90, 87 | 302.6301 ± 86.10161 | 301.6297 ± 74.72395 | 303.8266 ± 87.04586 |
| Uric acid, Week 24, n=58, 83, 86 | 299.6561 ± 78.45023 | 310.8726 ± 86.38513 | 308.5352 ± 91.73313 |
| Uric acid, Week 52/WD, n=60, 90, 89 | 305.2315 ± 78.61596 | 300.3079 ± 82.30325 | 308.0262 ± 92.43123 |
Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| Millimoles per Liter (mmol/L) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Chloride, BL, n=60, 93, 90 | 104.3 ± 1.97 | 104.2 ± 1.85 | 103.6 ± 1.60 |
| Chloride, Week 12, n=58, 90, 87 | 105.9 ± 2.05 | 105.6 ± 2.38 | 105.6 ± 2.14 |
| Chloride, Week 24, n=58, 83, 86 | 105.4 ± 2.04 | 105.0 ± 2.44 | 105.0 ± 2.16 |
| Chloride, Week 52/WD, n=60, 90, 89 | 105.6 ± 2.19 | 105.3 ± 2.41 | 104.8 ± 2.12 |
| CO2 content/Bicarbonate, BL, n=60, 93, 90 | 25.3 ± 2.02 | 25.0 ± 1.84 | 25.2 ± 1.95 |
| CO2 content/Bicarbonate, Week 12, n=58, 90, 87 | 24.9 ± 2.01 | 24.8 ± 2.13 | 25.4 ± 1.81 |
| CO2 content/Bicarbonate, Week 24, n=58, 83, 86 | 25.4 ± 2.26 | 25.3 ± 2.33 | 24.8 ± 2.32 |
| CO2 content/Bicarbonate, Week 52/WD, n=60, 90, 88 | 24.9 ± 2.03 | 25.3 ± 2.14 | 25.1 ± 2.04 |
| Glucose, BL, n=60, 93, 90 | 5.6685 ± 0.88699 | 5.7826 ± 0.98753 | 5.7669 ± 1.03176 |
| Glucose, Week 12, n=58, 90, 87 | 5.5606 ± 1.07679 | 5.7848 ± 1.01409 | 5.7647 ± 1.05233 |
| Glucose, Week 24, n=58, 83, 86 | 5.8228 ± 1.41235 | 5.8593 ± 0.97613 | 5.8169 ± 1.43353 |
| Glucose, Week 52/WD, n=60, 90, 89 | 5.4455 ± 1.05905 | 5.7743 ± 1.00636 | 5.8572 ± 1.17153 |
| Potassium, BL, n=60, 93, 90 | 4.04 ± 0.279 | 4.13 ± 0.332 | 4.12 ± 0.338 |
| Potassium, Week 12, n=58, 90, 87 | 4.17 ± 0.282 | 4.17 ± 0.366 | 4.16 ± 0.352 |
| Potassium, Week 24, n=58, 83, 86 | 4.14 ± 0.326 | 4.17 ± 0.390 | 4.16 ± 0.331 |
| Potassium, Week 52/WD, n=60, 90, 89 | 4.14 ± 0.333 | 4.17 ± 0.363 | 4.16 ± 0.306 |
| Sodium, BL, n=60, 93, 90 | 141.2 ± 1.53 | 141.3 ± 1.66 | 140.7 ± 1.59 |
| Sodium, Week 12, n=58, 90, 87 | 141.1 ± 1.62 | 140.7 ± 1.81 | 140.8 ± 1.47 |
| Sodium, Week 24, n=58, 83, 86 | 140.9 ± 1.23 | 141.1 ± 1.89 | 141.0 ± 1.69 |
| Sodium, Week 52/WD, n=60, 90, 89 | 141.3 ± 1.42 | 141.6 ± 1.62 | 141.2 ± 1.80 |
| Urea/BUN, BL, n=60, 93, 90 | 5.0658 ± 1.50071 | 5.0928 ± 1.38695 | 4.7116 ± 1.12591 |
| Urea/BUN, Week 12, n=58, 90, 87 | 5.0792 ± 1.18333 | 4.9865 ± 1.23302 | 4.7973 ± 1.37172 |
| Urea/BUN, Week 24, n=58, 83, 86 | 5.0177 ± 1.16880 | 4.9593 ± 1.23301 | 4.8510 ± 1.24616 |
| Urea/BUN, Week 52/WD, n=60, 90, 89 | 4.9932 ± 1.28828 | 4.9869 ± 1.41120 | 4.7120 ± 1.16694 |
Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| pH | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Urine pH, Baseline, n=60, 93, 90 | 6.33 ± 0.774 | 6.36 ± 0.883 | 6.46 ± 0.852 |
| Urine pH, Week 12, n=58, 90, 87 | 6.41 ± 0.726 | 6.36 ± 0.798 | 6.39 ± 0.833 |
| Urine pH, Week 24, n=58, 83, 86 | 6.27 ± 0.785 | 6.40 ± 0.878 | 6.33 ± 0.807 |
| Urine pH, Week 52/WD, n=60, 90, 89 | 6.25 ± 0.795 | 6.50 ± 0.775 | 6.42 ± 0.847 |
Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.
| ratio of urine density to water density | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Urine Specific Gravity, Baseline, n=60, 93, 90 | 1.0177 ± 0.00764 | 1.0177 ± 0.00830 | 1.0173 ± 0.00734 |
| Urine Specific Gravity, Week 12, n=58, 90, 87 | 1.0171 ± 0.00731 | 1.0167 ± 0.00789 | 1.0163 ± 0.00806 |
| Urine Specific Gravity, Week 24, n=58, 83, 86 | 1.0174 ± 0.00795 | 1.0180 ± 0.00755 | 1.0179 ± 0.00758 |
| Urine Specific Gravity, Week 52/WD, n=60, 90, 89 | 1.0160 ± 0.00689 | 1.0159 ± 0.00755 | 1.0156 ± 0.00811 |
Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace (TRA), 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.
| Participants | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| UOB, Neg, BL, n=60, 93, 90 | 51 | 79 | 81 |
| UOB, TRA, BL, n=60, 93, 90 | 6 | 5 | 2 |
| UOB, 1+, BL, n=60, 93, 90 | 2 | 5 | 2 |
| UOB, 2+, BL, n=60, 93, 90 | 1 | 3 | 3 |
| UOB, 3+, BL, n=60, 93, 90 | 0 | 1 | 2 |
| UOB, Neg, Week 12, n=58, 90, 87 | 50 | 79 | 75 |
| UOB, TRA, Week 12, n=58, 90, 87 | 2 | 4 | 5 |
| UOB, 1+, Week 12, n=58, 90, 87 | 4 | 2 | 3 |
| UOB, 2+, Week 12, n=58, 90, 87 | 2 | 3 | 1 |
| UOB, 3+, Week 12, n=58, 90, 87 | 0 | 2 | 3 |
| UOB, Neg, Week 24, n=58, 83, 86 | 49 | 71 | 78 |
| UOB, TRA, Week 24, n=58, 83, 86 | 4 | 6 | 2 |
| UOB, 1+, Week 24, n=58, 83, 86 | 1 | 1 | 4 |
| UOB, 2+, Week 24, n=58, 83, 86 | 3 | 3 | 0 |
| UOB, 3+, Week 24, n=58, 83, 86 | 1 | 2 | 2 |
| UOB, Neg, Week 52/WD, n=60, 90, 89 | 54 | 76 | 81 |
| UOB, TRA, Week 52/WD, n=60, 90, 89 | 4 | 4 | 2 |
| UOB, 1+, Week 52/WD, n=60, 90, 89 | 0 | 6 | 1 |
| UOB, 2+, Week 52/WD, n=60, 90, 89 | 1 | 3 | 3 |
| UOB, 3+, Week 52/WD, n=60, 90, 89 | 1 | 1 | 2 |
| UG, Neg, BL, n=60, 93, 90 | 58 | 93 | 87 |
| UG, TRA, BL, n=60, 93, 90 | 2 | 0 | 1 |
| UG, 1+, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UG, 2+, BL, n=60, 93, 90 | 0 | 0 | 2 |
| UG, 3+, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UG, Neg, Week 12, n=58, 90, 87 | 55 | 90 | 83 |
| UG, TRA, Week 12, n=58, 90, 87 | 2 | 0 | 0 |
| UG, 1+, Week 12, n=58, 90, 87 | 1 | 0 | 0 |
| UG, 2+, Week 12, n=58, 90, 87 | 0 | 0 | 1 |
| UG, 3+, Week 12, n=58, 90, 87 | 0 | 0 | 3 |
| UG, Neg, Week 24, n=58, 83, 86 | 53 | 80 | 82 |
| UG, TRA, Week 24, n=58, 83, 86 | 2 | 1 | 0 |
| UG, 1+, Week 24, n=58, 83, 86 | 2 | 1 | 1 |
| UG, 2+, Week 24, n=58, 83, 86 | 1 | 0 | 0 |
| UG, 3+, Week 24, n=58, 83, 86 | 0 | 1 | 3 |
| UG, Neg, Week 52/WD, n=60, 90, 89 | 59 | 87 | 84 |
| UG, TRA, Week 52/WD, n=60, 90, 89 | 0 | 3 | 3 |
| UG, 1+, Week 52/WD, n=60, 90, 89 | 1 | 0 | 0 |
| UG, 2+, Week 52/WD, n=60, 90, 89 | 0 | 0 | 1 |
| UG, 3+, Week 52/WD, n=60, 90, 89 | 0 | 0 | 1 |
| UK, Neg, BL, n=60, 93, 90 | 60 | 93 | 90 |
| UK, TRA, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UK, 1+, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UK, 2+, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UK, 3+, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UK, Neg, Week 12, n=58, 90, 87 | 58 | 89 | 86 |
| UK, TRA, Week 12, n=58, 90, 87 | 0 | 0 | 0 |
| UK, 1+, Week 12, n=58, 90, 87 | 0 | 1 | 1 |
| UK, 2+, Week 12, n=58, 90, 87 | 0 | 0 | 0 |
| UK, 3+, Week 12, n=58, 90, 87 | 0 | 0 | 0 |
| UK, Neg, Week 24, n=58, 83, 86 | 58 | 83 | 86 |
| UK, TRA, Week 24, n=58, 83, 86 | 0 | 0 | 0 |
| UK, 1+, Week 24, n=58, 83, 86 | 0 | 0 | 0 |
| UK, 2+, Week 24, n=58, 83, 86 | 0 | 0 | 0 |
| UK, 3+, Week 24, n=58, 83, 86 | 0 | 0 | 0 |
| UK, Neg, Week 52/WD, n=60, 90, 89 | 59 | 90 | 89 |
| UK, TRA, Week 52/WD, n=60, 90, 89 | 0 | 0 | 0 |
| UK, 1+, Week 52/WD, n=60, 90, 89 | 1 | 0 | 0 |
| UK, 2+, Week 52/WD, n=60, 90, 89 | 0 | 0 | 0 |
| UK, 3+, Week 52/WD, n=60, 90, 89 | 0 | 0 | 0 |
| UP, Neg, BL, n=60, 93, 90 | 55 | 76 | 79 |
| UP, TRA, BL, n=60, 93, 90 | 4 | 16 | 9 |
| UP, 1+, BL, n=60, 93, 90 | 1 | 1 | 2 |
| UP, 2+, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UP, 3+, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UP, Neg, Week 12, n=58, 90, 87 | 52 | 82 | 76 |
| UP, TRA, Week 12, n=58, 90, 87 | 5 | 5 | 7 |
| UP, 1+, Week 12, n=58, 90, 87 | 0 | 2 | 4 |
| UP, 2+, Week 12, n=58, 90, 87 | 1 | 0 | 0 |
| UP, 3+, Week 12, n=58, 90, 87 | 0 | 1 | 0 |
| UP, Neg, Week 24, n=58, 83, 86 | 50 | 73 | 80 |
| UP, TRA, Week 24, n=58, 83, 86 | 7 | 8 | 5 |
| UP, 1+, Week 24, n=58, 83, 86 | 1 | 1 | 1 |
| UP, 2+, Week 24, n=58, 83, 86 | 0 | 1 | 0 |
| UP, 3+, Week 24, n=58, 83, 86 | 0 | 0 | 0 |
| UP, Neg, Week 52/WD, n=60, 90, 89 | 54 | 70 | 68 |
| UP, TRA, Week 52/WD, n=60, 90, 89 | 5 | 15 | 17 |
| UP, 1+, Week 52/WD, n=60, 90, 89 | 1 | 4 | 2 |
| UP, 2+, Week 52/WD, n=60, 90, 89 | 0 | 1 | 2 |
| UP, 3+, Week 52/WD, n=60, 90, 89 | 0 | 0 | 0 |
| UWBC, Neg, BL, n=60, 93, 90 | 53 | 79 | 82 |
| UWBC,TRA, BL, n=60, 93, 90 | 0 | 0 | 0 |
| UWBC,1+, BL, n=60, 93, 90 | 3 | 7 | 3 |
| UWBC,2+, BL, n=60, 93, 90 | 3 | 3 | 2 |
| UWBC,3+, BL, n=60, 93, 90 | 1 | 4 | 3 |
| UWBC,Neg, Week 12, n=58, 90, 87 | 52 | 73 | 77 |
| UWBC,TRA, Week 12, n=58, 90, 87 | 0 | 0 | 0 |
| UWBC,1+, Week 12, n=58, 90, 87 | 2 | 5 | 7 |
| UWBC,2+, Week 12, n=58, 90, 87 | 3 | 5 | 3 |
| UWBC,3+, Week 12, n=58, 90, 87 | 1 | 7 | 0 |
| UWBC,Neg, Week 24, n=58, 83, 86 | 50 | 70 | 78 |
| UWBC,TRA, Week 24, n=58, 83, 86 | 0 | 0 | 0 |
| UWBC,1+, Week 24, n=58, 83, 86 | 4 | 6 | 7 |
| UWBC,2+, Week 24, n=58, 83, 86 | 2 | 5 | 1 |
| UWBC,3+, Week 24, n=58, 83, 86 | 2 | 2 | 0 |
| UWBC,Neg, Week 52/WD, n=60, 90, 89 | 52 | 75 | 78 |
| UWBC,TRA, Week 52/WD, n=60, 90, 89 | 0 | 0 | 0 |
| UWBC,1+, Week 52/WD, n=60, 90, 89 | 4 | 6 | 2 |
| UWBC,2+, Week 52/WD, n=60, 90, 89 | 3 | 5 | 7 |
| UWBC,3+, Week 52/WD, n=60, 90, 89 | 1 | 4 | 2 |
Urine samples were collected for measurement of urinary cortisol excretion at the following scheduled time points: Baseline (Week 0), Week 24, and Week 52/WD. The 24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
| Nanomoles (nmol)/24 hours | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Week 24, n=19, 20, 28 | 1.0218 ± 42.309 | 1.0602 ± 64.825 | 0.9698 ± 67.211 |
| Week 52/WD, n=18, 19, 30 | 0.8956 ± 48.231 | 1.0802 ± 73.912 | 0.8190 ± 41.301 |
Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Millimeters of Mercury (mmHg) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| SBP, Week 12, n=58, 90, 88 | -1.6 ± 9.54 | 1.2 ± 11.42 | 0.7 ± 13.01 |
| SBP, Week 24, n=58, 83, 86 | -0.7 ± 11.76 | -1.6 ± 12.88 | 0.1 ± 9.39 |
| SBP Week 52/WD, n=60, 92, 89 | -1.5 ± 9.34 | 0.5 ± 11.95 | 0.9 ± 11.66 |
| DBP, Week 12, n=58, 90, 88 | -0.3 ± 8.09 | 1.0 ± 8.63 | -2.3 ± 9.28 |
| DBP, Week 24, n=58, 83, 86 | -0.7 ± 8.46 | 0.5 ± 9.43 | -1.1 ± 7.82 |
| DBP, Week 52/WD, n=60, 92, 89 | -0.1 ± 8.55 | 1.5 ± 10.13 | -0.1 ± 9.20 |
Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Beats/Minute | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Week 12, n=58, 90, 88 | 0.9 ± 12.27 | -0.6 ± 9.02 | 1.3 ± 8.54 |
| Week 24, n=58, 83, 86 | 0.1 ± 9.24 | 0.1 ± 9.18 | 1.1 ± 9.97 |
| Week 52/WD, n=60, 92, 89 | -1.2 ± 10.91 | -1.4 ± 9.62 | 1.1 ± 9.10 |
A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Baseline\[Week -2\], Week 12, 24 and Week 52/WD) in the treatment period. Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal (Abn) findings. Any abnormal ECG, including those that worsen from Baseline, and determined clinically significant by the assessment of the investigator were recorded as CS.
| Participants | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Baseline, Abn NCS, n=60, 93, 90 | 19 | 22 | 11 |
| Baseline, Abn CS, n=60, 93, 90 | 0 | 0 | 0 |
| Week 12, Abn NCS, n=58, 90, 88 | 11 | 17 | 10 |
| Week 12, Abn CS, n=58, 90, 88 | 0 | 0 | 0 |
| Week 24, Abn NCS, n=58, 83, 86 | 12 | 18 | 9 |
| Week 24, Abn CS, n=58, 83, 86 | 0 | 0 | 0 |
| Week 52/WD, Abn NCS, n=60, 90, 89 | 10 | 16 | 12 |
| Week 52/WD, Abn CS, n=60, 90, 89 | 0 | 2 | 0 |
A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.
| Participants | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Number of Participants With Severe Asthma Exacerbation During the Study Treatment | 3 | 9 | 16 |
Change from Baseline in AM and PM PEF at 52 weeks of evaluation period during study treatment was recorded in the dairy record card. The Baseline value was calculated as the mean of all available data recorded during the7 days immediately prior to the treatment start date (including Day 1: Day 1 is treatment start date). The PEF is defined as the greatest rate of airflow that can be achieved during forced exhalation beginning with the lungs fully inflated.
| Litres per Minute (L/min) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| PEF AM, Week 0-52 | 18.29 ± 36.304 | 23.98 ± 38.668 | 12.38 ± 32.295 |
| PEF PM, Week 0-52 | 20.23 ± 35.274 | 26.29 ± 40.510 | 15.64 ± 30.772 |
The Baseline value was calculated as the mean of all available data recorded during the 7 days immediately prior to Visit 2 (treatment assignment visit). Participants entered their asthma symptom score in the patient diary twice daily (morning and evening). Daytime asthma symptom scores: 0-no asthma symptoms, 1-one episode of short-time asthma symptoms, 2-two or more episodes of short-time asthma symptoms, 3-asthma symptoms occurring during most part of daytime without interference with daily life activities, 4-asthma symptoms occurring during most part of daytime with interference with daily life activities, 5-severe asthma symptoms that disable working or daily life activities. Nighttime asthma symptom scores: 0-no asthma symptoms, 1-one awakening due to asthma symptoms, 2-two or more awakenings due to asthma symptoms, 3-asthma symptoms almost prevented the participant from sleeping, 4-severe asthma symptoms completely prevented from sleeping.
| Scores on a scale | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Change From Baseline in Asthma Symptom Score During the Study Treatment | -0.14 ± 0.638 | -0.14 ± 0.856 | -0.19 ± 0.771 |
Participants who were symptom free for 24-hours were assessed. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.
| Percentage of symptom-free days | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment | 6.79 ± 20.382 | 6.51 ± 28.290 | 8.19 ± 26.975 |
The time span during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.
| Percentage of rescue free 24-hour period | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Week 0-12, n=60, 93, 90 | 97.94 ± 9.553 | 95.51 ± 16.427 | 92.79 ± 17.462 |
| Week 13-24, n=58, 91, 88 | 97.60 ± 7.521 | 95.94 ± 13.477 | 94.35 ± 16.990 |
| Week 25-36, n=58, 84, 87 | 97.99 ± 8.757 | 95.24 ± 14.685 | 94.14 ± 15.713 |
| Week 37-52, n=57, 79, 86 | 98.38 ± 7.253 | 95.71 ± 13.382 | 95.13 ± 14.705 |
| Week 0-52, n=60, 93, 90 | 98.01 ± 7.736 | 95.76 ± 13.556 | 94.28 ± 15.169 |
Salbutamol inhaler was used as the rescue medication. Participants entered the number of rescue medication inhalations in the patient diary twice daily (morning and evening).
| Number of inhalations | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Week 0-12, n=60, 93, 90 | 5.15 ± 31.288 | 7.32 ± 27.667 | 13.42 ± 43.889 |
| Week 13-24, n=58, 91, 88 | 5.12 ± 19.094 | 6.65 ± 23.257 | 12.56 ± 54.154 |
| Week 25-36, n=58, 84, 87 | 6.02 ± 36.358 | 7.45 ± 25.058 | 14.01 ± 70.642 |
| Week 37-52, n=57, 79, 86 | 7.75 ± 50.851 | 7.73 ± 22.285 | 17.78 ± 97.092 |
| Week 0-52, n=60, 93, 90 | 23.28 ± 132.467 | 27.13 ± 90.038 | 56.23 ± 253.508 |
Collected over On-treatment non-serious adverse events (AEs), defined as those events occurring while participants were on treatment, up to and including the day after the last dose in each treatment period (up to 52 weeks), are reported. SAEs, defined as those events o. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FF/GW642444 100/25 µg | — | 4/60 (6.7%) | 52/60 (86.7%) |
| FF/GW642444 200/25 µg | — | 7/93 (7.5%) | 77/93 (82.8%) |
| FF 100 µg | — | 1/90 (1.1%) | 72/90 (80%) |
| Event | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 2/60 | 0/93 | 0/90 |
| PneumoniaInfections and infestations | 1/60 | 1/93 | 0/90 |
| Chronic sinusitisInfections and infestations | 1/60 | 0/93 | 0/90 |
| TonsillitisInfections and infestations | 1/60 | 0/93 | 0/90 |
| Nasal septum deviationRespiratory, thoracic and mediastinal disorders | 1/60 | 0/93 | 0/90 |
| Rhinitis hypertrophicRespiratory, thoracic and mediastinal disorders | 1/60 | 0/93 | 0/90 |
| Colitis ischaemicGastrointestinal disorders | 1/60 | 0/93 | 0/90 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/60 | 0/93 | 1/90 |
| DiverticulitisInfections and infestations | 0/60 | 1/93 | 0/90 |
| Nasal polypsRespiratory, thoracic and mediastinal disorders | 0/60 | 1/93 | 0/90 |
| Event | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 37/60 | 57/93 | 49/90 |
| BronchitisInfections and infestations | 8/60 | 18/93 | 12/90 |
| Oral candidiasisInfections and infestations | 3/60 | 13/93 | 3/90 |
| PharyngitisInfections and infestations | 7/60 | 12/93 | 12/90 |
| GastroenteritisInfections and infestations | 7/60 | 0/93 | 7/90 |
| InfluenzaInfections and infestations | 2/60 | 9/93 | 7/90 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 5/60 | 6/93 | 6/90 |
| HeadacheNervous system disorders | 5/60 | 4/93 | 5/90 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/60 | 6/93 | 7/90 |
| EczemaSkin and subcutaneous tissue disorders | 4/60 | 3/93 | 3/90 |
| Age, Continuous(Years) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg | Total |
|---|---|---|---|---|
| Mean | 51.3 ± 13.74 | 52.6 ± 15.05 | 46.8 ± 15.46 | 50.1 ± 15.06 |
| Gender(Participants) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg | Total |
|---|---|---|---|---|
| Female | 38 | 49 | 54 | 141 |
| Male | 22 | 44 | 36 | 102 |
| Race/Ethnicity, Customized(Participants) | FF/GW642444 100/25 µg | FF/GW642444 200/25 µg | FF 100 µg | Total |
|---|---|---|---|---|
| Asian - Japanese Heritage | 60 | 93 | 90 | 243 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jul 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol